Vaxcyte, Inc. financial data

Symbol
PCVX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
825 Industrial Road, Ste. 300, San Carlos, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
SutroVax, Inc. (to 4/3/2020)
Latest financial report
10-K - Q4 2024 - Feb 25, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.61K % +22.1%
Debt-to-equity 5.2 % -33.7%
Return On Equity -17.4 % +45.8%
Return On Assets -16.5 % +44.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 129M shares +18.4%
Common Stock, Shares, Outstanding 125M shares +31%
Entity Public Float 7.2B USD +75.6%
Common Stock, Value, Issued 128K USD +30.6%
Weighted Average Number of Shares Outstanding, Basic 122M shares +25.6%
Weighted Average Number of Shares Outstanding, Diluted 122M shares +25.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 477M USD +43.4%
General and Administrative Expense 92.9M USD +53.1%
Operating Income (Loss) -570M USD -21.7%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -464M USD -15.3%
Earnings Per Share, Basic -3.8 USD/shares +8.21%
Earnings Per Share, Diluted -3.8 USD/shares +8.21%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 388M USD -2.41%
Other Assets, Current 4.46M USD +111%
Assets, Current 1.79B USD +63.1%
Property, Plant and Equipment, Net 198M USD +149%
Operating Lease, Right-of-Use Asset 72.1M USD +133%
Other Assets, Noncurrent 64.4M USD +71.3%
Assets 3.51B USD +149%
Accounts Payable, Current 48.5M USD +232%
Employee-related Liabilities, Current 20.6M USD +85.9%
Accrued Liabilities, Current 29.1M USD -51.3%
Liabilities, Current 140M USD -3.55%
Operating Lease, Liability, Noncurrent 65.2M USD +195%
Other Liabilities, Noncurrent 100K USD
Liabilities 205M USD +22.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -3.87M USD -2264%
Retained Earnings (Accumulated Deficit) -1.39B USD -50.2%
Stockholders' Equity Attributable to Parent 3.31B USD +166%
Liabilities and Equity 3.51B USD +149%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -159M USD -234%
Net Cash Provided by (Used in) Financing Activities 818M USD +1869%
Net Cash Provided by (Used in) Investing Activities -451M USD -0.66%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 125M shares +31%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 214M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 389M USD -2.35%
Deferred Tax Assets, Valuation Allowance 446M USD +54.8%
Deferred Tax Assets, Gross 468M USD +57.4%
Operating Lease, Liability 71.1M USD +143%
Payments to Acquire Property, Plant, and Equipment 5.68M USD +1.23%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -468M USD -16.5%
Lessee, Operating Lease, Liability, to be Paid 100M USD +170%
Property, Plant and Equipment, Gross 214M USD +141%
Operating Lease, Liability, Current 5.89M USD -17.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 9.64M USD -2.04%
Lessee, Operating Lease, Liability, to be Paid, Year One 10.9M USD +23.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure -11.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 29M USD +268%
Lessee, Operating Lease, Liability, to be Paid, Year Three 8.61M USD +197%
Deferred Tax Assets, Operating Loss Carryforwards 196M USD +44.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 9.53M USD +114%
Lessee, Operating Lease, Liability, to be Paid, Year Four 9.39M USD +215%
Operating Lease, Payments 11.5M USD +55.8%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 999K USD +40.3%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%